Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HOLLY L HAKE HARRIS

Allopathic & Osteopathic Physicians Dermatology

NPI
1538159207
CMS profile
890706
Location
SOUTH BEND, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$29.68

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $29.68 2

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Biotech, Inc. $29.68 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HOLLY L HAKE HARRIS

NPI 1538159207 · CMS profile ID 890706

Allopathic & Osteopathic Physicians / Dermatology

SOUTH BEND, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538159207?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538159207?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538159207?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1538159207?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $29.68 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $13.1808/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788358765 CMS
Janssen Biotech, Inc. $16.5007/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788358763 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,931.99 7
PY2021 $29.68 2
PY2022 $77.19 4
PY2023 $448.39 16
PY2024 $189.69 8
PY2025 $60.71 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,042.82 1
PY2025 Principal investigator $214,389.75 98
PY2024 Recipient $6,347.66 1
PY2024 Principal investigator $293,318.73 162
PY2023 Principal investigator $348,782.35 197
PY2022 Recipient $100.00 2
PY2022 Principal investigator $164,469.18 81
PY2021 Principal investigator $449,676.56 73
PY2020 Recipient $15,456.30 2
PY2020 Principal investigator $642,662.67 80
PY2019 Recipient $418,491.34 8
PY2019 Principal investigator $1,194,399.32 72

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

82 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AbbVie Inc. $1,325.20 12/30/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC
M16-045 No dispute reported 06/30/2026 721202893
Principal investigator 1 AbbVie Inc. $1,453.70 12/30/2020 Non-covered Recipient Entity
QCARE SITE SERVICES INC
M15-997 No dispute reported 06/30/2026 721203623
Principal investigator 1 AbbVie Inc. $1,453.70 12/30/2020 Non-covered Recipient Entity
QCARE SITE SERVICES INC
M15-997 No dispute reported 06/30/2026 721203625
Principal investigator 1 PFIZER INC. $5,852.60 12/17/2020 Non-covered Recipient Entity
The South Bend Clinic LLP
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742894871
Principal investigator 1 PFIZER INC. $1,600.30 12/09/2020 Non-covered Recipient Entity
The South Bend Clinic LLP and Holly Hake Harris MD
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742894873
Principal investigator 1 PFIZER INC. $535.60 12/03/2020 Non-covered Recipient Entity
The South Bend Clinic LLP
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742894933
Principal investigator 1 AbbVie Inc. $5,852.50 12/01/2020 Non-covered Recipient Entity
QCARE SITE SERVICES INC
M15-997 No dispute reported 06/30/2026 721198417
Principal investigator 1 PFIZER INC. $9,575.80 11/21/2020 Non-covered Recipient Entity
The South Bend Clinic LLP
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742903783
Principal investigator 1 PFIZER INC. $1,600.30 11/11/2020 Non-covered Recipient Entity
The South Bend Clinic LLP and Holly Hake Harris MD
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742903587
Principal investigator 1 PFIZER INC. $5,102.50 10/30/2020 Non-covered Recipient Entity
The South Bend Clinic LLP
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742904077
Principal investigator 1 AbbVie Inc. $2,180.90 10/29/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC
M16-045 No dispute reported 06/30/2026 721192977
Principal investigator 1 AbbVie Inc. $1,491.40 10/29/2020 Non-covered Recipient Entity
QCARE SITE SERVICES INC
M15-997 No dispute reported 06/30/2026 721193475
Principal investigator 1 AbbVie Inc. $1,453.70 10/29/2020 Non-covered Recipient Entity
QCARE SITE SERVICES INC
M15-997 No dispute reported 06/30/2026 721193477
Principal investigator 1 Eli Lilly and Company $676.47 10/27/2020 Covered Recipient Teaching Hospital
H. LEE MOFFITT CANCER CENTER
A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 No dispute reported 06/30/2026 728728053
Principal investigator 1 PFIZER INC. $1,914.90 10/17/2020 Non-covered Recipient Entity
The South Bend Clinic LLP
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742903781
Principal investigator 1 PFIZER INC. $1,600.30 10/02/2020 Non-covered Recipient Entity
The South Bend Clinic LLP and Holly Hake Harris MD
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742903787
Principal investigator 1 PFIZER INC. $7,553.00 10/02/2020 Non-covered Recipient Entity
The South Bend Clinic LLP
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742904073
Principal investigator 1 AbbVie Inc. $2,180.90 09/30/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC
M16-045 No dispute reported 06/30/2026 721188291
Principal investigator 1 AbbVie Inc. $3,340.30 09/30/2020 Non-covered Recipient Entity
QCARE SITE SERVICES INC
M15-997 No dispute reported 06/30/2026 721189057
Principal investigator 1 AbbVie Inc. $2,907.40 09/30/2020 Non-covered Recipient Entity
QCARE SITE SERVICES INC
M15-997 No dispute reported 06/30/2026 721189059
Principal investigator 1 PFIZER INC. $70.00 09/18/2020 Non-covered Recipient Entity
The South Bend Clinic Center For Research
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742880255
Principal investigator 1 AbbVie Inc. $1,886.60 08/28/2020 Non-covered Recipient Entity
QCARE SITE SERVICES INC
M15-997 No dispute reported 06/30/2026 721183589
Principal investigator 1 PFIZER INC. $123.50 08/22/2020 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742904053
Principal investigator 1 PFIZER INC. $8,095.00 08/19/2020 Non-covered Recipient Entity
The South Bend Clinic LLP
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742903143
Principal investigator 1 PFIZER INC. $3,200.60 08/19/2020 Non-covered Recipient Entity
The South Bend Clinic LLP and Holly Hake Harris MD
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742903233
Principal investigator 1 AbbVie Inc. $1,437.00 07/30/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC
M16-045 No dispute reported 06/30/2026 721177735
Principal investigator 1 AbbVie Inc. $26.97 07/22/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC
M16-045 No dispute reported 06/30/2026 721176385
Recipient Eli Lilly and Company $15,339.00 07/21/2020 Covered Recipient Physician A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 No dispute reported 06/30/2026 728720445
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $10,889.46 07/14/2020 Non-covered Recipient Entity
Advanced Clinical Research Incorporated
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 736758687
Recipient Eli Lilly and Company $117.30 07/09/2020 Covered Recipient Physician A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 728719109
Principal investigator 1 AbbVie Inc. $500.72 07/07/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC
M15-997 No dispute reported 06/30/2026 721175189
Principal investigator 1 AbbVie Inc. $134.85 07/07/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC
M15-997 No dispute reported 06/30/2026 721175199
Principal investigator 1 PFIZER INC. $1,600.30 07/04/2020 Non-covered Recipient Entity
The South Bend Clinic LLP and Holly Hake Harris MD
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742903229
Principal investigator 1 AbbVie Inc. $166.81 07/01/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC
M15-997 No dispute reported 06/30/2026 721174071
Principal investigator 1 AbbVie Inc. $3,177.80 07/01/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC
M15-997 No dispute reported 06/30/2026 721174075
Principal investigator 1 AbbVie Inc. $4,969.50 07/01/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC
M15-997 No dispute reported 06/30/2026 721174077
Principal investigator 1 PFIZER INC. $3,200.60 06/17/2020 Non-covered Recipient Entity
The South Bend Clinic LLP and Holly Hake Harris MD
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742903301
Principal investigator 1 PFIZER INC. $1,750.00 06/17/2020 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742904057
Principal investigator 1 AbbVie Inc. $2,959.80 06/01/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC MAIN CAMPUS
M16-045 No dispute reported 06/30/2026 721169413
Principal investigator 1 AbbVie Inc. $1,694.20 05/29/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC MAIN CAMPUS
M15-997 No dispute reported 06/30/2026 721168881
Principal investigator 1 AbbVie Inc. $4,909.70 05/29/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC MAIN CAMPUS
M15-997 No dispute reported 06/30/2026 721168883
Principal investigator 1 PFIZER INC. $25,581.90 05/29/2020 Non-covered Recipient Entity
The South Bend Clinic LLP and Holly Hake Harris MD
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742905397
Principal investigator 1 AbbVie Inc. $1,694.20 04/29/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC
M15-997 No dispute reported 06/30/2026 721162815
Principal investigator 1 AbbVie Inc. $4,834.30 04/29/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC
M15-997 No dispute reported 06/30/2026 721162817
Principal investigator 1 AbbVie Inc. $2,564.60 03/30/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC MAIN CAMPUS
M16-045 No dispute reported 06/30/2026 721158097
Principal investigator 1 AbbVie Inc. $2,634.40 03/27/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC MAIN CAMPUS
M15-997 No dispute reported 06/30/2026 721157381
Principal investigator 1 AbbVie Inc. $7,371.20 03/27/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC MAIN CAMPUS
M15-997 No dispute reported 06/30/2026 721157383
Principal investigator 1 PFIZER INC. $1,808.30 03/12/2020 Non-covered Recipient Entity
The South Bend Clinic LLP
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742905697
Principal investigator 1 Eli Lilly and Company $5,475.00 03/02/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 728750255
Principal investigator 1 AbbVie Inc. $2,588.00 02/28/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC MAIN CAMPUS
M16-045 No dispute reported 06/30/2026 721152985
Principal investigator 1 PFIZER INC. $9,846.98 02/28/2020 Non-covered Recipient Entity
The South Bend Clinic LLP
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742905735
Principal investigator 1 PFIZER INC. $2,236.65 02/26/2020 Non-covered Recipient Entity
The South Bend Clinic LLP
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742905655
Principal investigator 1 AbbVie Inc. $1,559.00 02/18/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC MAIN CAMPUS
M15-997 No dispute reported 06/30/2026 721150905
Principal investigator 1 AbbVie Inc. $3,080.30 02/18/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC MAIN CAMPUS
M15-997 No dispute reported 06/30/2026 721150907
Principal investigator 1 AbbVie Inc. $80.92 02/12/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC MAIN CAMPUS
M16-045 No dispute reported 06/30/2026 721150283
Principal investigator 1 AbbVie Inc. $745.00 02/12/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC MAIN CAMPUS
M16-045 No dispute reported 06/30/2026 721150285
Principal investigator 1 AbbVie Inc. $152.36 02/12/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC MAIN CAMPUS
M15-997 No dispute reported 06/30/2026 721150343
Principal investigator 1 Eli Lilly and Company $430.65 02/10/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 728741431
Principal investigator 1 AbbVie Inc. $1,100.40 02/06/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC MAIN CAMPUS
M16-045 No dispute reported 06/30/2026 721150009
Principal investigator 1 AbbVie Inc. $713.00 02/05/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC MAIN CAMPUS
M16-045 No dispute reported 06/30/2026 721149615
Principal investigator 1 PFIZER INC. $1,665.30 02/04/2020 Non-covered Recipient Entity
The South Bend Clinic LLP
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742905739
Principal investigator 1 Eli Lilly and Company $2,281.00 02/03/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A PHASE 2, MULTICENTER, RANDOMIZED, PARALLEL-ARM, PLACEBO- CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH MODERATE-TO- SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 728747451
Principal investigator 1 Eli Lilly and Company $6,205.00 02/03/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 No dispute reported 06/30/2026 728749641
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $21,767.85 01/28/2020 Non-covered Recipient Entity
South Bend Clinic Cardiology
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis No dispute reported 06/30/2026 736762409
Principal investigator 1 Eli Lilly and Company $3,702.00 01/28/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 728737595
Principal investigator 1 Eli Lilly and Company $21.90 01/28/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 728739491
Principal investigator 1 Eli Lilly and Company $73.54 01/28/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3375880 IN ADULT SUBJECTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: THE ADMIRE STUDY No dispute reported 06/30/2026 728745441
Principal investigator 1 Eli Lilly and Company $598.08 01/28/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 728745443
Principal investigator 1 Eli Lilly and Company $17,437.00 01/28/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 728749475
Principal investigator 1 PFIZER INC. $1,665.30 01/23/2020 Non-covered Recipient Entity
The South Bend Clinic LLP
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742905443
Principal investigator 1 AbbVie Inc. $3,350.70 01/21/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC MAIN CAMPUS
M15-997 No dispute reported 06/30/2026 721146259
Principal investigator 1 AbbVie Inc. $5,539.20 01/21/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC MAIN CAMPUS
M15-997 No dispute reported 06/30/2026 721146261
Principal investigator 1 Eli Lilly and Company $6,397.00 01/21/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 728741421
Principal investigator 1 Eli Lilly and Company $14,925.00 01/17/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3375880 IN ADULT SUBJECTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: THE ADMIRE STUDY No dispute reported 06/30/2026 728750251
Principal investigator 1 Eli Lilly and Company $1,217.91 01/15/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 No dispute reported 06/30/2026 728743667
Principal investigator 1 AbbVie Inc. $6,606.10 01/13/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC MAIN CAMPUS
M16-045 No dispute reported 06/30/2026 721145217
Principal investigator 1 Eli Lilly and Company $2,091.50 01/09/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 728741427
Principal investigator 1 AbbVie Inc. $215.55 01/08/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC MAIN CAMPUS
M16-045 No dispute reported 06/30/2026 721144731
Principal investigator 1 PFIZER INC. $8,292.70 01/08/2020 Non-covered Recipient Entity
The South Bend Clinic LLP
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 COADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO 18 YEARS OF AGE WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742905741
Principal investigator 1 Eli Lilly and Company $271,708.00 01/07/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 No dispute reported 06/30/2026 728737591
Principal investigator 1 Eli Lilly and Company $14,212.00 01/07/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF IXEKIZUMAB IN PATIENTS FROM 6 TO LESS THAN 18 YEARS OF AGE WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS No dispute reported 06/30/2026 728739487
Principal investigator 1 Eli Lilly and Company $67,748.00 01/07/2020 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 728739495

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $0.00 1
PY2025 Value of interest $109,356.47 1
PY2024 Amount invested $2,443.72 1
PY2024 Value of interest $109,356.47 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $106,912.75 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $154,320.92 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $88,340.48 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $80,642.76 1
PY2019 Amount invested $80,595.00 1
PY2019 Value of interest $806,985.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

7 records · PY2019–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 Digital Diagnostics Inc. $0.00 $109,356.47 Shares Owned by Immediate Family (Ben Clark) Immediate family member No dispute reported 06/30/2026 1254605365
PY2024 Digital Diagnostics Inc. $2,443.72 $109,356.47 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 1153967797
PY2023 Digital Diagnostics Inc. $0.00 $106,912.75 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 1060331987
PY2022 Digital Diagnostics Inc. $0.00 $154,320.92 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 961154523
PY2021 Digital Diagnostics Inc. $0.00 $88,340.48 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 855625849
PY2020 Digital Diagnostics Inc. $0.00 $80,642.76 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 737170185
PY2019 IDx Technologies Inc. $80,595.00 $806,985.00 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 676471935